{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:28:32Z","timestamp":1745328512334},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Chang Gung Memorial Hospital (CMRPG3G1591) Research Program in Taiwan","award":["CMRPG3G1591"],"award-info":[{"award-number":["CMRPG3G1591"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00520-020-05321-3","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T17:04:16Z","timestamp":1579799056000},"page":"4771-4779","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Ting-Yu","family":"Chiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chih","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Whi","family":"Jane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"5321_CR1","unstructured":"International agency for research on cancer (2019) Cancer fact sheets: colorectal cancer. Available from: https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers? cancer=6&type=0&sex=0. Ministry of Health Welfare, Taiwan, ROC. 2017 statistics cause of death. Available from: http:\/\/www.doh.gov.tw. Accessed May 16, 2019"},{"key":"5321_CR2","unstructured":"Taiwan cancer registry (2019) 2018 Annual Report. Available from: http:\/\/crs.cph.ntu.edu.tw\/. Accessed May 16, 2019"},{"key":"5321_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.critrevonc.2017.01.007","volume":"111","author":"M Berretta","year":"2017","unstructured":"Berretta M, Alessandrini L, De Divitiis C et al (2017) Serum and tissue markers in colorectal cancer: state of art. Crit Rev Oncol Hematol 111:103\u2013116. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.01.007","journal-title":"Crit Rev Oncol Hematol"},{"key":"5321_CR4","first-page":"70","volume":"24","author":"D Stulhofer Buzina","year":"2016","unstructured":"Stulhofer Buzina D, Martinac I, Ledic Drvar D et al (2016) Adverse reaction to cetuximab, an epidermal growth factor receptor inhibitor. Acta Dermatovenerol Croati 24:70\u201372","journal-title":"Acta Dermatovenerol Croati"},{"key":"5321_CR5","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"KJ Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169\u20131176","journal-title":"Br J Dermatol"},{"key":"5321_CR6","doi-asserted-by":"publisher","unstructured":"D'Alessio A, Cecchini S, Di Mauro D et al (2016) Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Tumori 102. https:\/\/doi.org\/10.5301\/tj.5000579","DOI":"10.5301\/tj.5000579"},{"key":"5321_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/annonc\/mdj084","volume":"17","author":"G Folprecht","year":"2006","unstructured":"Folprecht G, Lutz MP, Schoffski P et al (2006) Cetuximab and irinotecan\/5-fluorouracil\/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450\u2013456. https:\/\/doi.org\/10.1093\/annonc\/mdj084","journal-title":"Ann Oncol"},{"key":"5321_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12029-013-9485-7","volume":"44","author":"J Giuliani","year":"2013","unstructured":"Giuliani J, Marzola M (2013) Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor? J Gastrointest Cancer 44:241\u2013345. https:\/\/doi.org\/10.1007\/s12029-013-9485-7","journal-title":"J Gastrointest Cancer"},{"key":"5321_CR9","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.22034\/APJCP.2018.19.8.2325","volume":"19","author":"S Takada","year":"2018","unstructured":"Takada S, Sagawa T, Fujikawa K, Tahatsu K, Fukai Y, Hashishita H, Takahashi Y, Endo M (2018) Skin disorders and primary tumor location as prognostic factors in patients with metastatic colorectal cancer treated with cetuximab and chemotherapy. Asian Pac J Cancer Prev 19:2325\u20132330. https:\/\/doi.org\/10.22034\/APJCP.2018.19.8.2325","journal-title":"Asian Pac J Cancer Prev"},{"key":"5321_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5582\/bst.2018.01246","volume":"12","author":"Y Peng","year":"2019","unstructured":"Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C, Cui H (2019) Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends 12:537\u2013552. https:\/\/doi.org\/10.5582\/bst.2018.01246","journal-title":"Biosci Trends"},{"key":"5321_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/nur.21722","volume":"39","author":"A Charalambous","year":"2016","unstructured":"Charalambous A, Charalambous M (2016) \u201cI lost my image, the image others know me by\u201d: findings from a hermeneutic phenomenological study of patients living with treatment-induced cutaneous toxicities. Res Nurs Health 39:187\u2013196. https:\/\/doi.org\/10.1002\/nur.21722","journal-title":"Res Nurs Health"},{"key":"5321_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40261-015-0373-8","volume":"36","author":"C Charles","year":"2016","unstructured":"Charles C, Razavi D, Bungener C, Mateus C, Lanoy E, Verschoore M, Dauchy S, Robert C (2016) Impact of skin toxicities associated with targeted cancer therapies on body image: a prospective study. Clin Drug Investig 36:235\u2013242. https:\/\/doi.org\/10.1007\/s40261-015-0373-8","journal-title":"Clin Drug Investig"},{"key":"5321_CR13","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.2147\/OTT.S127795","volume":"16","author":"M De Tursi","year":"2017","unstructured":"De Tursi M, Zilli M, Carella C et al (2017) Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. OncoTargets Ther 16:3007\u20133015. https:\/\/doi.org\/10.2147\/OTT.S127795 eCollection 2017","journal-title":"OncoTargets Ther"},{"key":"5321_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"SL Boone","year":"2007","unstructured":"Boone SL, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152\u2013159","journal-title":"Oncology"},{"key":"5321_CR15","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","volume":"1","author":"DA Karnofsky","year":"1948","unstructured":"Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic. Cancer 1:634\u2013656","journal-title":"Cancer"},{"key":"5321_CR16","unstructured":"National comprehensive cancer network (2018) NCCN guidelines for patients: colon cancers 2018. Available From: http:\/\/www.nccn.org. Accessed May 16, 2019"},{"key":"5321_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00002820-197810000-00003","volume":"1","author":"R McCorkle","year":"1978","unstructured":"McCorkle R, Young K (1978) Development of symptom distress scale. Cancer Nurs 1:373\u2013378","journal-title":"Cancer Nurs"},{"key":"5321_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1017\/S1352465813000556","volume":"42","author":"D Veale","year":"2014","unstructured":"Veale D, Eshkevari E, Kanakam N, Ellison N, Costa A, Werner T (2014) The appearance anxiety inventory: validation of a process measure in the treatment of body dysmorphic disorder. Behav Cogn Psychother 42:605\u2013616. https:\/\/doi.org\/10.1017\/S1352465813000556","journal-title":"Behav Cogn Psychother"},{"key":"5321_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00520-012-1623-4","volume":"21","author":"LI Wagner","year":"2013","unstructured":"Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME (2013) The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer 21:1033\u20131041. https:\/\/doi.org\/10.1007\/s00520-012-1623-4","journal-title":"Support Care Cancer"},{"key":"5321_CR20","unstructured":"National cancer institute (2010) Common terminology criteria for adverse events (CTCAE), Version 4.0. Available from: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed May 16, 2019"},{"key":"5321_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.critrevonc.2017.10.011","volume":"120","author":"P Bonomo","year":"2017","unstructured":"Bonomo P, Loi M, Desideri I et al (2017) Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: a systematic review. Crit Rev Oncol Hematol 120:98\u2013110. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.10.011","journal-title":"Crit Rev Oncol Hematol"},{"key":"5321_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351\u20131357. https:\/\/doi.org\/10.1200\/JCO.2008.21.7828","journal-title":"J Clin Oncol"},{"key":"5321_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","volume":"8","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Segaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 8:509\u2013522. https:\/\/doi.org\/10.1007\/s00520-009-0744-x","journal-title":"Support Care Cancer"},{"key":"5321_CR24","first-page":"33","volume":"2","author":"TB Fitzpatrick","year":"1975","unstructured":"Fitzpatrick TB (1975) Sun and skin. Journal de M\u00e9decine Esth\u00e9tique [in French] 2:33\u201334","journal-title":"Journal de M\u00e9decine Esth\u00e9tique [in French]"},{"key":"5321_CR25","unstructured":"Australian Radiation Protection and Nuclear Safety Agency (2007) Fitzpatrick skin phenotype. Available from: https:\/\/www.arpansa.gov.au\/sites\/default\/files\/legacy\/pubs\/RadiationProtection\/FitzpatrickSkinType.pdf. Accessed May 16, 2019"},{"key":"5321_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/lsm.23103","volume":"51","author":"MWM Chan","year":"2019","unstructured":"Chan MWM, Shek SY, Yeung CK, Chan HH (2019) A prospective study in the treatment of lentigines in Asian skin using 532\u2009nm picosecond Nd:YAG laser. Lasers Surg Med 51:767\u2013773","journal-title":"Lasers Surg Med"},{"key":"5321_CR27","doi-asserted-by":"publisher","unstructured":"Jo HC, Kim DY (2019) Correlation between light absorbance and skin color using fabricated skin phantoms with different colors. Lasers Med Sci 1\u20138. https:\/\/doi.org\/10.1007\/s10103-019-02888-0","DOI":"10.1007\/s10103-019-02888-0"},{"key":"5321_CR28","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/pon.5067","volume":"28","author":"YL Chang","year":"2019","unstructured":"Chang YL, Huang BS, Hung TM, Lin CY, Chen SC (2019) Factors influencing body image in posttreatment oral cavity cancer patients. Psychooncology 28:1127\u20131133. https:\/\/doi.org\/10.1002\/pon.5067","journal-title":"Psychooncology"},{"key":"5321_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pon.4939","volume":"28","author":"SC Chen","year":"2019","unstructured":"Chen SC, Huang BS, Hung TM et al (2019) Impact of a behavior change program and health education on social interactions in survivors of head and neck cancer: randomized controlled trial. Psychooncology 28:293\u2013300. https:\/\/doi.org\/10.1002\/pon.4939","journal-title":"Psychooncology"},{"key":"5321_CR30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/1471-2407-12-438","volume":"12","author":"J Thaler","year":"2012","unstructured":"Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Ba\u00f1os A, K\u00f6hne CH (2012) Skin toxicity and quality of life in patients with metastatic cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 12:438. https:\/\/doi.org\/10.1186\/1471-2407-12-438","journal-title":"BMC Cancer"},{"key":"5321_CR31","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1128\/MCB.00302-14","volume":"34","author":"M Dahlhoff","year":"2014","unstructured":"Dahlhoff M, Frances D, Kloepper JE, Paus R, Sch\u00e4fer M, Niemann C, Schneider MR (2014) Overexpression of epigen during embryonic development induces reversible, epidermal growth factor receptor-dependent sebaceous gland hyperplasia. Mol Cell Biol 34:3086\u20133095. https:\/\/doi.org\/10.1128\/MCB.00302-14","journal-title":"Mol Cell Biol"},{"key":"5321_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803\u2013812","journal-title":"Nat Rev Cancer"},{"key":"5321_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","volume":"43","author":"AF Galimont-Collen","year":"2007","unstructured":"Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43:845\u2013851","journal-title":"Eur J Cancer"},{"key":"5321_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/pon.4494","volume":"27","author":"P Esser","year":"2018","unstructured":"Esser P, Mehnert A, Johansen C, Hornemann B, Dietz A, Ernst J (2018) Body image mediates the effect of cancer-related stigmatization on depression: a new target for intervention. Psychooncology 27:193\u2013198. https:\/\/doi.org\/10.1002\/pon.4494","journal-title":"Psychooncology"},{"key":"5321_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/pon.2048","volume":"22","author":"SM Phelan","year":"2013","unstructured":"Phelan SM, Griffin JM, Jackson GL, Zafar SY, Hellerstedt W, Stahre M, Nelson D, Zullig LL, Burgess DJ, van Ryn M (2013) Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer. Psychooncology 22:65\u201373. https:\/\/doi.org\/10.1002\/pon.2048","journal-title":"Psychooncology"},{"key":"5321_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","volume":"14","author":"AC Rosen","year":"2013","unstructured":"Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14:327\u2013333. https:\/\/doi.org\/10.1007\/s40257-013-0021-0","journal-title":"Am J Clin Dermatol"},{"key":"5321_CR37","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1002\/cncr.25090","volume":"116","author":"SS Joshi","year":"2010","unstructured":"Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116:3916\u20133923. https:\/\/doi.org\/10.1002\/cncr.25090","journal-title":"Cancer"},{"key":"5321_CR38","first-page":"48","volume":"12","author":"DL Stanculeanu","year":"2017","unstructured":"Stanculeanu DL, Zob D, Toma OC, Georgescu B, Papagheorghe L, Mihaila RI (2017) Cutaneous toxicities of molecular targeted therapies. Maedica (Buchar) 12:48\u201354","journal-title":"Maedica (Buchar)"},{"key":"5321_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/DAD.0000000000000504","volume":"39","author":"JJ Lee","year":"2017","unstructured":"Lee JJ, Kroshinsky D, Hoang MP (2017) Cutaneous reactions to targeted therapy. Am J Dermatopathol 39:67\u201382. https:\/\/doi.org\/10.1097\/DAD.0000000000000504","journal-title":"Am J Dermatopathol"},{"key":"5321_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.12968\/bjon.2019.28.3.180","volume":"28","author":"A Davidson","year":"2019","unstructured":"Davidson A, Williams J (2019) Factors affecting quality of life in patients experiencing facial disfigurement due to surgery for head and neck cancer. Br J Nurs 28:180\u2013184. https:\/\/doi.org\/10.12968\/bjon.2019.28.3.180","journal-title":"Br J Nurs"},{"key":"5321_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1503\/cjs.014717","volume":"62","author":"DH Hirpara","year":"2019","unstructured":"Hirpara DH, Azin A, Mulcahy V et al (2019) The impact of surgical modality on self-reported body image, quality of life and survivorship after anterior resection for colorectal cancer\u2013a mixed methods study. Can J Surg 62:1\u20138. https:\/\/doi.org\/10.1503\/cjs.014717","journal-title":"Can J Surg"},{"key":"5321_CR42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00520-015-2781-y","volume":"24","author":"JMK Clabbers","year":"2016","unstructured":"Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven K, Kaptein AA (2016) Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer 24:513\u2013521. https:\/\/doi.org\/10.1007\/s00520-015-2781-y","journal-title":"Support Care Cancer"},{"key":"5321_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/CMAR.S52256","volume":"5","author":"RJ Bensadoun","year":"2013","unstructured":"Bensadoun RJ, Humbert P, Krutman J, Luger T, Triller R, Rougier A, Seite S, Dreno B (2013) Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Manag Res 5:401\u2013408. https:\/\/doi.org\/10.2147\/CMAR.S52256 eCollection 2013","journal-title":"Cancer Manag Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-020-05321-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:57:15Z","timestamp":1611277035000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-020-05321-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["5321"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05321-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of Chang Gung Medical Foundation Institutional Review Board in Taiwan, and a permission certificate was obtained (Number: 201701198B0).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}